Innovation in biosciences is leading to the growth of the pharmaceutical market, with sales reaching $1.6 trillion. Medical devices and diagnostics contribute an additional half a trillion. Digital health is also expanding rapidly, with 80% now coming from biotech.
In the last 20 years, we have seen a shift from small molecule drugs to biotech developments. Today’s top drugs, such as mRNA vaccines and monoclonal antibodies, come from the field of biotechnology.
These new methods, including gene and RNA therapies, are transforming medicine. Most of this innovation was initiated by academic research. For example, the antibody revolution began in the 1970s and has since led to over 100 antibody products on the market, generating a value of over $160 billion.
How does innovation in the biosciences turn into commercial products?
The transformation of academic discoveries into commercial products is complex. You can publish findings, license technologies, or create spin-outs. Funding is often challenging in the academic sphere, as investors tend to favor products that are developed in industrial settings.
Creating a successful spin-out requires high-quality research, technology transfer offices that facilitate rather than hinder innovation, startup investors, and a favorable tax regime.
Conclusions
In conclusion, every country should strive for the commercialization of biomedicine. Healthcare systems can be both clients and partners in innovation. Digital health is a rapidly growing field that requires fewer pre-commercial investments but still needs significant efforts in validation and sales. By addressing these challenges, we can unlock the potential of academic innovations to transform medicine and drive commercial success.
Watch the lecture by Mike Romanos (Associate Dean for Enterprise, Faculty of Medicine, Imperial College & Co-Founder and Interim CEO, NK:IO Ltd, UK) delivered as part of the conference on Health-Biotechnology-Economy Synergy Structures.
The seminar was organized by Komvos-Node in collaboration with the ARISTEiA Institute USA as part of the Bio³ conference organized by Bioinnovation.
Coordinators of the conference: Konstantinos Drosatos (University of Cincinnati, USA, President of ARISTEiA and General Secretary of Komvos’ Board of Directors) and Nikos Kyrpides (Berkeley National Laboratory, USA and Board Member of Komvos).
The conference is sponsored by DEMO ABEE pharmaceutics.
Komvos-Node is supported by the accounting-consulting firm Ecovis-Onetax.
Piraeus Bank in Komvos’ main sponsor, always supporting its vision.
Read more here about Komvos’ activities in the biotechnology sector.
